Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study

Cecilia Linde, Michael R. Gold, William T. Abraham, Martin St John Sutton, Stefano Ghio, Jeff Cerkvenik, Claude Daubert

Research output: Contribution to journalArticlepeer-review

Abstract

BackgroundThe benefit of cardiac resynchronization therapy (CRT) among patients with mild heart failure (HF), reduced left ventricular (LV) function and wide QRS is well established. We studied the long-term stability of CRT.MethodsREVERSE was a randomized, double-blind study on CRT in NYHA Class I and II HF patients with QRS ≥120 ms and left ventricular ejection fraction (LVEF) ≤40%. After the randomized phase, all were programmed to CRT ON and prospectively followed through 5 years for functional capacity, echocardiography, HF hospitalizations, mortality, and adverse events. We report the results of the 419 patients initially assigned to CRT ON.FindingsThe mean follow-up time was 54.8 ± 13.0 months. After 2 years, the functional and LV remodelling improvements were maximal. The 6-min hall walk increased by 18.8 ± 102.3 m and the Minnesota and Kansas City scores improved by 8.2 ± 17.8 and 8.2 ± 17.2 units, respectively. The mean decrease in left ventricular end-systolic volume index and left ventricular end-diastolic volume index was 23.5 ± 34.1 mL/m2 (P <0.0001) and 25.4 ± 37.0 mL/m2 (P <0.0001) and the mean increase in LVEF 6.0 ± 10.8% (P <0.0001) with sustained improvement thereafter. The annualized and 5-year mortality was 2.9 and 13.5% and the annualized and 5-year rate of death or first HF hospitalization 6.4, and 28.1%. The 5-year LV lead-related complication rate was 12.5%.ConclusionIn patients with mild HF, CRT produced reverse LV remodelling accompanied by very low mortality and need for heart failure hospitalization. These effects were sustained over 5 years. Cardiac resynchronization therapy in addition to optimal medical therapy produces long-standing clinical benefits in mild heart failure.Clinical Trial RegistrationClinicaltrials.gov identifier NCT00271154.

Original languageEnglish
Pages (from-to)2592-2599
Number of pages8
JournalEuropean Heart Journal
Volume34
Issue number33
DOIs
Publication statusPublished - Sep 7 2013

Keywords

  • Cardiac resynchronization therapy
  • Electrical dyssynchrony
  • Heart failure
  • Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the resynchronization reverses remodeling in systolic left ventricular dysfunction (REVERSE) study'. Together they form a unique fingerprint.

Cite this